Our team has developed a collection of PDX models derived from primary tumors or liver metastasis. We have also generated clinical trial associated xenografts (CTAX) from patients enrolled in early phase trials with new experimental drugs. Our collection is partially annotated for clinical, mutational and gene expression data.
The Vall d’Hebron Institute of Oncology is a member of the EurOPDX Consortium . EurOPDX is supported by the European Union's Horizon 2020 research and innovation programme under the grant agreement No. 731105 EDIReX